Raffaele Colombo/LinkedIn
Mar 11, 2025, 09:56
Raffaele Colombo: Sacituzumab tirumotecan was approved for a second indication by NMPA in China
Raffaele Colombo, Associate Director of Medicinal Chemistry at Zymeworks, shared a post on X:
“Sacituzumab tirumotecan approved for a second indication by NMPA in China:
for the treatment of adult patients with EGFR-mutant locally advanced or metastatic non-squamous NSCLC following progression on EGFR-tyrosine kinase inhibitor therapy and platinum-based chemotherapy.”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
May 9, 2025, 12:42
May 9, 2025, 12:26
May 9, 2025, 11:53